Dry Eye Syndrome Clinical Trial
In the elderly population, dry eye syndrome is a highly prevalent ocular disease. One
mainstay of therapy for patients suffering from dry eye syndrome is the use of topically
administered lubricants. One of the main disadvantages of the formulations currently
available for the treatment of DES is the short residency time on the ocular surface, which
increases the need for a frequent instillation of the lubricant.
Recently, Croma Pharma has introduced chitosan-N-acetylcysteine eye drops, designed for
treatment of symptoms related to DES. Based on theoretical considerations and animal
experiments, the new chitosan derivative may show an increased adhesion to mucins of the
ocular surface and may therefore considerably increase the residence on the ocular surface.
This, in turn, would limit the need for frequent treatment and decrease the burden for the
patients.
It has been shown in recent Phase I studies that chitosan-N-acetylcysteine eye drops are
safe and well tolerated after single and repeated instillation. The current study seeks to
investigate the ocular residency time after a single dose and after 5 day b.i.d. treatment.
For this purpose 2 cohorts are planned: In Cohort I, chitosan-N-acetylcysteine eye drops
will be instilled once in one randomly chosen eye, whereas the fellow eye will receive
placebo. Measurements of tear film thickness will be performed with optical coherence
tomography (OCT) before instillation and 10 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 10
hours, 12 hours and 24 hours after instillation. In addition, ocular scattering of the tear
film will be assessed with an Optical Quality Analysis System (OQAS) at the same timepoints.
Determination of break up time (BUT) will be performed before and after instillation of the
eye drops.
In Cohort II, chitosan-N-acetylcysteine eye drops will be instilled once daily in one eye
and b.i.d. in the fellow eye on five consecutive days. Measurements of tear film thickness
with OCT and OQAS will be performed every study day before the morning instillation and the
day after the last instillation. Additionally, patients will be asked to answer the ocular
surface disease index (OSDI©) on day 1 and day 6. BUT will be determined before and after
instillation of the eye drops.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02597803 -
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
|
Phase 2/Phase 3 | |
| Completed |
NCT02522312 -
A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients
|
N/A | |
| Completed |
NCT01863368 -
Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining
|
N/A | |
| Completed |
NCT01753687 -
Correlation of Different Signs for Assessment of Dry Eye Syndrome
|
N/A | |
| Completed |
NCT01198782 -
Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%
|
Phase 4 | |
| Completed |
NCT01212471 -
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
|
Phase 3 | |
| Completed |
NCT01162954 -
Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00544713 -
Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery
|
N/A | |
| Completed |
NCT00535054 -
Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms
|
N/A | |
| Completed |
NCT00344721 -
A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome
|
N/A | |
| Completed |
NCT03830359 -
Efficacy, Safety of T2769 in Dry Eye Disease
|
N/A | |
| Completed |
NCT04139122 -
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02758327 -
Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops
|
Phase 4 | |
| Completed |
NCT02066051 -
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
|
N/A | |
| Completed |
NCT01970917 -
Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects
|
Phase 4 | |
| Completed |
NCT02092207 -
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
|
Phase 2 | |
| Completed |
NCT01541891 -
Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome
|
Phase 2 | |
| Completed |
NCT01252121 -
Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline
|
N/A | |
| Completed |
NCT00765804 -
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
|
Phase 2 | |
| Completed |
NCT00565669 -
Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
|
N/A |